

Pigmented Villonodular Synovitis (Musculoskeletal) - Drugs in Development, 2021

<https://marketpublishers.com/r/PFFE16284B6AEN.html>

Date: October 2021

Pages: 86

Price: US\$ 2,000.00 (Single User License)

ID: PFFE16284B6AEN

Abstracts

Pigmented Villonodular Synovitis (Musculoskeletal) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis - Drugs In Development, 2021, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape. Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules

developed by Companies in Phase II and Phase I stages are 5 and 1 respectively.

Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route

of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Pigmented Villonodular Synovitis - Overview

Pigmented Villonodular Synovitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pigmented Villonodular Synovitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Checkmate Pharmaceuticals Inc

Merck KGaA

Nippon Chemiphar Co Ltd

Novartis AG

SynOx Therapeutics Ltd

Pigmented Villonodular Synovitis - Drug Profiles

avelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabiralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vidutolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zaltoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pigmented Villonodular Synovitis - Dormant Projects

Pigmented Villonodular Synovitis - Discontinued Products

Pigmented Villonodular Synovitis - Product Development Milestones

Featured News & Press Releases

Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Pigmented Villonodular Synovitis, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pigmented Villonodular Synovitis - Pipeline by Bristol-Myers Squibb Co, 2021
Pigmented Villonodular Synovitis - Pipeline by Checkmate Pharmaceuticals Inc, 2021
Pigmented Villonodular Synovitis - Pipeline by Merck KGaA, 2021
Pigmented Villonodular Synovitis - Pipeline by Nippon Chemiphar Co Ltd, 2021
Pigmented Villonodular Synovitis - Pipeline by Novartis AG, 2021
Pigmented Villonodular Synovitis - Pipeline by SynOx Therapeutics Ltd, 2021
Pigmented Villonodular Synovitis - Dormant Projects, 2021
Pigmented Villonodular Synovitis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Pigmented Villonodular Synovitis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

I would like to order

Product name: Pigmented Villonodular Synovitis (Musculoskeletal) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/PFFE16284B6AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PFFE16284B6AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970